Cara Therapeutics Inc (STU:69C)
€ 0.2506 -0.0086 (-3.32%) Market Cap: 14.16 Mil Enterprise Value: -22.43 Mil PE Ratio: 0 PB Ratio: 20.96 GF Score: 31/100

Cara Therapeutics Inc at JPMorgan Healthcare Conference Transcript

Jan 09, 2023 / 07:15PM GMT
Release Date Price: €9.84 (-2.28%)
Daniel G. Wolle
JPMorgan Chase & Co, Research Division - Analyst

Good morning, everyone. My name is Daniel Wolle. I'm one of the analysts on this mid-cap biotech team. It's my pleasure to introduce Chris Posner from Cara Therapeutics. Following his presentation, rest of management will come up to the -- from podium. You can ask questions or you can ask through the portal as well.

Without further idea, Chris?

Christopher A. Posner
Cara Therapeutics, Inc. - President, CEO & Director

Well, thank you, Daniel, and good morning, everyone. And before we dig in quickly on Slide 2, just a necessary reminder of our forward-looking statements in this presentation, and you could refer to this, and you could also refer to our filings, our regulatory filings on our website.

So let's dig in. What's our mission? Our mission at Cara is to be the world leader when it comes to the treatment of pruritus. Now pruritus is more than just a niche. It's a significantly debilitating condition, and it really impacts a patient's quality of life. And despite

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot